ADHD Medication and Predictors of Treatment Outcome
ADAPT
Naturalistic Study of ADHD Medication and Predictors of Treatment Outcome
3 other identifiers
observational
632
1 country
1
Brief Summary
ADHD medication of children and adolescents is becoming increasingly common. Clinical experience and scientific studies have proven that approximately 30% of children/adolescents with ADHD do not benefit from this treatment. However, there is insufficient knowledge about who these children are. All children and adolescents, who start treatment with ADHD medication at public Child and Adolescent Psychiatry units in Stockholm, on Gotland, an in Västerbotten, will be asked to participate in the study. The investigators intend to monitor the patients´clinical symptoms and possible side-effects after treatment start. The investigators will collect background information and saliva samples from the patient and his/her parents to be able to study if there are any genetic (hereditary) or other markers that can predict positive or negative outcomes of the ADHD medication. With this information, the investigators aim at, to a greater extent, be able to individualize treatment choices for children and adolescents with ADHD without unnecessary, costly and possibly unfavorable treatment attempts.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2015
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 30, 2014
CompletedFirst Posted
Study publicly available on registry
May 12, 2014
CompletedStudy Start
First participant enrolled
June 1, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2022
CompletedOctober 17, 2023
October 1, 2023
6.1 years
April 30, 2014
October 16, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
change in SNAP-IV Teacher and Parent rating scale (Swanson, Nolan and Pelham ADHD Rating Scale)
ADHD symptoms
at 3 months follow-up
change in P-SEC (Pediatric Side Effects Checklist)
Side-effect measure
at 3 months follow-up
Secondary Outcomes (34)
change in C-GAS (Children´s global assessment scale)
at 12 months follow-up
change in CGI-S (Clinical Global Impression- of Severity)
at 12 months follow-up
change in SNAP-IV Teacher and Parent rating scale
at 1 month follow-up
change in SNAP-IV Teacher and Parent rating scale
at 6 months follow-up
change in SNAP-IV Teacher and Parent rating scale
at 12 months follow-up
- +29 more secondary outcomes
Other Outcomes (2)
change in self-harm frequency
at 12 months follow-up
change in suicide attempt frequency
at 12 months follow-up
Study Arms (5)
Children with ADHD medication
Identified responders and non-responders in children/adolescents starting medication for treatment of ADHD in public child and adolescent psychiatric services in Stockholm, on Gotland, and in Västerbotten.
Lisdexamphetamine medication
Identified responders and non-responders in children/adolescents starting medication with lisdexamphetamine in public child and adolescent psychiatric services in Stockholm and on Gotland.
Atomoxetine medication
Identified responders and non-responders in children/adolescents starting medication with atomoxetine in public child and adolescent psychiatric services in Stockholm and on Gotland.
Methylphenidate medication
Identified responders and non-responders in children/adolescents starting medication with methylphenidate in public child and adolescent psychiatric services in Stockholm and on Gotland.
Guanfacine medication
Identified responders and non-responders in children/adolescents starting medication with guanfacine in public child and adolescent psychiatric services in Stockholm and on Gotland.
Interventions
Eligibility Criteria
All children/adolescents starting ADHD medication at the public child and adolescent psychiatry services in Stockholm and on Gotland
You may qualify if:
- Clinical diagnosis of ADHD
- Starting medication against ADHD symptoms with atomoxetine, methylphenidate, lisdexamphetamine, or guanfacine
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Division for Child and Adolescent Psychiatry in Stockholm
Stockholm, Stockholm County, Sweden
Related Publications (2)
Lilja MM, Lichtenstein P, Serlachius E, Bhagia J, Malmberg K, Malm C, Lenhard F, Halldner L. Can response to ADHD medication be predicted? Eur Child Adolesc Psychiatry. 2025 Aug;34(8):2431-2442. doi: 10.1007/s00787-025-02650-8. Epub 2025 Jan 29.
PMID: 39875602DERIVEDLilja MM, Sandblom E, Lichtenstein P, Serlachius E, Hellner C, Bhagia J, Halldner L. The effect of autistic traits on response to and side-effects of pharmacological ADHD treatment in children with ADHD: results from a prospective clinical cohort. J Neurodev Disord. 2022 Mar 6;14(1):17. doi: 10.1186/s11689-022-09424-2.
PMID: 35249540DERIVED
Biospecimen
Saliva
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 12 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD, PhD
Study Record Dates
First Submitted
April 30, 2014
First Posted
May 12, 2014
Study Start
June 1, 2015
Primary Completion
July 1, 2021
Study Completion
June 1, 2022
Last Updated
October 17, 2023
Record last verified: 2023-10